

Cardio-oncology Related to Heart Failure

Heart Failure Clinics

13, 297-309

DOI: [10.1016/j.hfc.2016.12.002](https://doi.org/10.1016/j.hfc.2016.12.002)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Left Ventricular Dysfunction in Cancer Treatment. JACC: Heart Failure, 2018, 6, 87-95.	1.9	37
2	Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy. Molecular and Cellular Toxicology, 2018, 14, 247-254.	0.8	11
3	Light control of RTK activity: from technology development to translational research. Chemical Science, 2020, 11, 10019-10034.	3.7	7
4	The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications. Frontiers in Pharmacology, 2021, 12, 701390.	1.6	19
5	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	1.0	213
6	Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies. Methodist DeBakey Cardiovascular Journal, 2021, 15, 250.	0.5	7
7	Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity. Biomedicines, 2022, 10, 520.	1.4	14
9	Exploring Key Genes and Pathways of Cardiac Hypertrophy Based on Bioinformatics. Disease Markers, 2022, 2022, 1-8.	0.6	3
10	Cardio-oncology: Implications for Clinical Practice for Women. Current Cardiology Reports, 2022, 24, 1685-1698.	1.3	1
11	EGFR inhibition leads to enhanced desmosome assembly and cardiomyocyte cohesion via ROCK activation. JCI Insight, 2023, 8, .	2.3	4